Insights

Why Opko Health Stock Is Jumping Today

What happened
Shares of Opko Health (NASDAQ: OPK) were jumping 13.5% higher as of 12:31 p.m. ET on Tuesday. The gain came after the company announced its first-quarter results following the market close on Monday.
Opko reported Q1 revenue of $329.2 million. Although this result reflected a sharp decline from the $545.2 million in revenue generated in the prior-year period, it beat the Zacks consensus estimate of close to $310 million.
The company posted a Q1 net loss of $55.4 million, or $0.08 per share — in line with expectations. In the first quarter of 2021, Opko recorded earnings of $31.1 million, or $0.05 per share.
Opko also announced on Monday that it has acquired ModeX Therapeutics in an all-stock deal valued at $300 million. ModeX focuses on developing immune therapies for treating cancer and infectious diseases.
So what
Investors shrugged off Opko’s revenue decline in the first quarter. It was widely expected that the company wouldn’t make nearly as much in COVID-19 testing sales.
The acquisition of ModeX could be good for Opko over the long term. ModeX co-founders Elias Zerhouni and Gary Nabel joined Opko’s board of directors as part of the transaction. Zerhouni will serve as Opko’s President and board vice-chairman. Nabel is taking the position of Chief Innovation Officer. In addition, ModeX’s lead independent director Alexis Borisy is joining Opko’s board of directors.
Image source: Getty Images.

Now what
Opko was badly in need of a positive catalyst, with the healthcare stock down more than 40% year to date. The addition of new blood to its board could be just what the doctor ordered. 
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. –

What happened

Shares of Opko Health (NASDAQ: OPK) were jumping 13.5% higher as of 12:31 p.m. ET on Tuesday. The gain came after the company announced its first-quarter results following the market close on Monday.

Opko reported Q1 revenue of $329.2 million. Although this result reflected a sharp decline from the $545.2 million in revenue generated in the prior-year period, it beat the Zacks consensus estimate of close to $310 million.

The company posted a Q1 net loss of $55.4 million, or $0.08 per share — in line with expectations. In the first quarter of 2021, Opko recorded earnings of $31.1 million, or $0.05 per share.

Opko also announced on Monday that it has acquired ModeX Therapeutics in an all-stock deal valued at $300 million. ModeX focuses on developing immune therapies for treating cancer and infectious diseases.

So what

Investors shrugged off Opko’s revenue decline in the first quarter. It was widely expected that the company wouldn’t make nearly as much in COVID-19 testing sales.

The acquisition of ModeX could be good for Opko over the long term. ModeX co-founders Elias Zerhouni and Gary Nabel joined Opko’s board of directors as part of the transaction. Zerhouni will serve as Opko’s President and board vice-chairman. Nabel is taking the position of Chief Innovation Officer. In addition, ModeX’s lead independent director Alexis Borisy is joining Opko’s board of directors.

Image source: Getty Images.

Now what

Opko was badly in need of a positive catalyst, with the healthcare stock down more than 40% year to date. The addition of new blood to its board could be just what the doctor ordered. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US & HK* Trades. Click Here!